Starpharma Holdings Limited (ASX:SPL – Get Free Report) insider Robert Thomas bought 250,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 10th. The stock was purchased at an average cost of A$0.17 ($0.11) per share, with a total value of A$43,500.00 ($28,064.52).
Robert Thomas also recently made the following trade(s):
- On Monday, April 15th, Robert Thomas acquired 100,000 shares of Starpharma stock. The stock was purchased at an average cost of A$0.13 ($0.08) per share, with a total value of A$13,000.00 ($8,387.10).
Starpharma Price Performance
The company has a debt-to-equity ratio of 9.08, a current ratio of 5.60 and a quick ratio of 5.65.
Starpharma Company Profile
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom.
Featured Stories
- Five stocks we like better than Starpharma
- What is a Secondary Public Offering? What Investors Need to Know
- United Airlines Soars on Earnings Beat
- Insider Selling Explained: Can it Inform Your Investing Choices?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Insider Trading – What You Need to Know
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
